The phenomenon of pseudoprogression in cancer immunotherapy: is everything so unambiguous?
When evaluating the effect of therapy for malignant neoplasms with inhibitors of CTLA-4, PD-1 and PD-L1, the phenomenon of pseudoprogression may occur. Pseudoprogression is an increase in the volume of tumor tissue due to immunocompetent cells (lymphocytes, macrophages) mobilized into the tumor focu...
Guardado en:
Autores principales: | Vladislav O. Sarzhevskiy, Vladimir Ia. Melnichenko, Irina V. Panshina, Nikita E. Mochkin, Vladimir S. Bogatyrov, Maria M. Borshevetskaya, Elena G. Smirnova, Anna E. Bannikova, Anastasia A. Samoylova, Aysel A. Mamedova, Anatolij A. Rukavitsin, Sergei S. Vasilev, Oleg Iu. Bronov |
---|---|
Formato: | article |
Lenguaje: | RU |
Publicado: |
IP Habib O.N.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/087c99ed4f454995bde9965434ae6e7f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma
por: Virginia Liberini, et al.
Publicado: (2021) -
Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
por: Peiyi Xie, et al.
Publicado: (2021) -
Dual immunological blockade in the treatment of metastatic non-small cell lung cancer: reality and perspectives
por: Denis I. Yudin, et al.
Publicado: (2021) -
Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy
por: Chi Yan, et al.
Publicado: (2021) -
Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma
por: Yan Li, et al.
Publicado: (2021)